

# Elizabeth A Shephard

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9529377/publications.pdf>

Version: 2024-02-01

61  
papers

2,935  
citations

159573

30  
h-index

168376

53  
g-index

65  
all docs

65  
docs citations

65  
times ranked

2790  
citing authors

#	ARTICLE	IF	CITATIONS
1	Missense mutation in flavin-containing mono-oxygenase 3 gene, FMO3, underlies fish-odour syndrome. <i>Nature Genetics</i> , 1997, 17, 491-494.	21.4	253
2	Trimethylamine and Trimethylamine N-Oxide, a Flavin-Containing Monooxygenase 3 (FMO3)-Mediated Host-Microbiome Metabolic Axis Implicated in Health and Disease. <i>Drug Metabolism and Disposition</i> , 2016, 44, 1839-1850.	3.3	248
3	A guide to the identification of metabolites in NMR-based metabonomics/metabolomics experiments. <i>Computational and Structural Biotechnology Journal</i> , 2016, 14, 135-153.	4.1	243
4	Organization and evolution of the flavin-containing monooxygenase genes of human and mouse. <i>Pharmacogenetics and Genomics</i> , 2004, 14, 117-130.	5.7	151
5	The molecular biology of the flavin-containing monooxygenases of man. <i>Chemico-Biological Interactions</i> , 1995, 96, 17-32.	4.0	135
6	Quantification and cellular localization of expression in human skin of genes encoding flavin-containing monooxygenases and cytochromes P450 2A2. Abbreviations: FMO, flavin-containing monooxygenase; CYP, cytochrome P450; KGM, keratinocyte growth medium; DMEM, Dulbecco's modified Eagle's medium. <i>Biochemical Pharmacology</i> , 2001, 62, 777-786.	4.4	123
7	The Flavin-containing Monooxygenase 2 Gene (FMO2) of Humans, but Not of Other Primates, Encodes a Truncated, Nonfunctional Protein. <i>Journal of Biological Chemistry</i> , 1998, 273, 30599-30607.	3.4	122
8	Flavin-containing monooxygenases: mutations, disease and drug response. <i>Trends in Pharmacological Sciences</i> , 2008, 29, 294-301.	8.7	115
9	Cell-, tissue-, sex- and developmental stage-specific expression of mouse flavin-containing monooxygenases (Fmos). <i>Biochemical Pharmacology</i> , 2004, 68, 73-83.	4.4	106
10	Trimethylaminuria and a human FMO3 mutation database. <i>Human Mutation</i> , 2003, 22, 209-213.	2.5	98
11	Orphan Receptor Promiscuity in the Induction of Cytochromes P450 by Xenobiotics. <i>Journal of Biological Chemistry</i> , 2001, 276, 12822-12826.	3.4	92
12	Drug metabolism by flavin-containing monooxygenases of human and mouse. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2017, 13, 167-181.	3.3	82
13	Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is mediated by the orphan nuclear receptor constitutive androstane receptor (CAR) and requires steroid co-activator 1 (SRC-1) and the transcription factor Sp1. <i>Biochemical Journal</i> , 2001, 355, 71-78.	3.7	81
14	Compound heterozygosity for missense mutations in the flavin-containing monooxygenase 3 (FMO3) gene in patients with fish-odour syndrome. <i>Pharmacogenetics and Genomics</i> , 2000, 10, 799-807.	5.7	64
15	Xenobiotic induction of cytochrome P450 2B1 (CYP2B1) is mediated by the orphan nuclear receptor constitutive androstane receptor (CAR) and requires steroid co-activator 1 (SRC-1) and the transcription factor Sp1. <i>Biochemical Journal</i> , 2001, 355, 71.	3.7	63
16	Maintenance and induction in co-cultured rat hepatocytes of components of the cytochrome P450-mediated mono-oxygenase. <i>Biochemical Pharmacology</i> , 1993, 45, 1583-1591.	4.4	61
17	Structural Organization of the Human Flavin-Containing Monooxygenase 3 Gene (FMO3), the Favored Candidate for Fish-Odor Syndrome, Determined Directly from Genomic DNA. <i>Genomics</i> , 1997, 46, 260-267.	2.9	51
18	GENETIC POLYMORPHISMS OF FLAVIN-CONTAINING MONOOXYGENASE (FMO). <i>Drug Metabolism Reviews</i> , 2002, 34, 523-532.	3.6	50

#	ARTICLE	IF	CITATIONS
19	Quantification of cytochrome P450 reductase gene expression in human tissues. Archives of Biochemistry and Biophysics, 1992, 294, 168-172.	3.0	44
20	Flavin-containing monooxygenase 3 (FMO3): genetic variants and their consequences for drug metabolism and disease. Xenobiotica, 2020, 50, 19-33.	1.1	44
21	A novel mutation in the flavin-containing monooxygenase 3 gene, FMO3, that causes fish-odour syndrome: activity of the mutant enzyme assessed by proton NMR spectroscopy. Pharmacogenetics and Genomics, 2000, 10, 439-451.	5.7	43
22	The potentially deleterious functional variant flavin-containing monooxygenase 2*1 is at high frequency throughout sub-Saharan Africa. Pharmacogenetics and Genomics, 2008, 18, 877-886.	1.5	43
23	Localization of cytochrome P-450 gene expression in normal and diseased human liver by in situ hybridization of wax-embedded archival material. Hepatology, 1992, 16, 682-687.	7.3	42
24	The phenotype of a flavin-containing monooxygenase knockout mouse implicates the drug-metabolizing enzyme FMO1 as a novel regulator of energy balance. Biochemical Pharmacology, 2014, 90, 88-95.	4.4	41
25	Flavin-Containing Monooxygenase 1 Catalyzes the Production of Taurine from Hypotaurine. Drug Metabolism and Disposition, 2020, 48, 378-385.	3.3	40
26	The phenotype of a knockout mouse identifies flavin-containing monooxygenase 5 (FMO5) as a regulator of metabolic ageing. Biochemical Pharmacology, 2015, 96, 267-277.	4.4	39
27	Human Flavin-Containing Monooxygenase 2.1 Catalyzes Oxygenation of the Antitubercular Drugs Thiacetazone and Ethionamide. Drug Metabolism and Disposition, 2009, 37, 178-186.	3.3	38
28	Mutation, polymorphism and perspectives for the future of human flavin-containing monooxygenase 3. Mutation Research - Reviews in Mutation Research, 2006, 612, 165-171.	5.5	37
29	Cloning and sequence analysis of a rat liver cDNA coding for a phenobarbital-inducible microheterogeneous cytochrome P-450 variant: regulation of its messenger level by xenobiotics. Gene, 1983, 26, 41-52.	2.2	33
30	Molecular evolution and balancing selection in the flavin-containing monooxygenase 3 gene (FMO3). Pharmacogenetics and Genomics, 2007, 17, 827-839.	1.5	33
31	Alternative promoters and repetitive DNA elements define the species-dependent tissue-specific expression of the <i>FMO1</i> genes of human and mouse. Biochemical Journal, 2007, 406, 491-499.	3.7	30
32	Effect of Flavin-Containing Monooxygenase Genotype, Mouse Strain, and Gender on Trimethylamine N-oxide Production, Plasma Cholesterol Concentration, and an Index of Atherosclerosis. Drug Metabolism and Disposition, 2018, 46, 20-25.	3.3	30
33	Clinical utility gene card for: Trimethylaminuria “ update 2014. European Journal of Human Genetics, 2015, 23, 1269-1269.	2.8	25
34	Identification of Flavin-Containing Monooxygenase 5 (FMO5) as a Regulator of Glucose Homeostasis and a Potential Sensor of Gut Bacteria. Drug Metabolism and Disposition, 2017, 45, 982-989.	3.3	25
35	Transfection of Liver In Vivo by Biolistic Particle Delivery: Its Use in the Investigation of Cytochrome P450 Gene Regulation. Molecular Biotechnology, 2002, 20, 145-152.	2.4	23
36	Deletion of the mouse <i>Fmo1</i> gene results in enhanced pharmacological behavioural responses to imipramine. Pharmacogenetics and Genomics, 2009, 19, 289-299.	1.5	22

#	ARTICLE	IF	CITATIONS
37	Relationships between flavin-containing monoxygenase 3 ( <i>FMO3</i> ) genotype and trimethylaminuria phenotype in a Japanese population. <i>British Journal of Clinical Pharmacology</i> , 2014, 77, 839-851.	2.4	18
38	A highly sensitive liquid chromatography electrospray ionization mass spectrometry method for quantification of TMA, TMAO and creatinine in mouse urine. <i>MethodsX</i> , 2017, 4, 310-319.	1.6	17
39	Clinical utility gene card for: Trimethylaminuria. <i>European Journal of Human Genetics</i> , 2012, 20, 4-5.	2.8	16
40	The potential of knockout mouse lines in defining the role of flavin-containing monooxygenases in drug metabolism. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2010, 6, 1083-1094.	3.3	15
41	Metabolism and Pharmacokinetics of the Anti-Tuberculosis Drug Ethionamide in a Flavin-Containing Monooxygenase Null Mouse. <i>Pharmaceuticals</i> , 2012, 5, 1147-1159.	3.8	14
42	Metabolic Biomarkers of Ageing in C57BL/6J Wild-Type and Flavin-Containing Monooxygenase 5 ( <i>FMO5</i> )-Knockout Mice. <i>Frontiers in Molecular Biosciences</i> , 2018, 5, 28.	3.5	14
43	Effects of the Anticonvulsant, Valproate, on the Expression of Components of the Cytochrome P450-Mediated Monooxygenase System and Glutathione S-Transferases. <i>FEBS Journal</i> , 1995, 231, 337-343.	0.2	10
44	Endogenous Roles of Mammalian Flavin-Containing Monooxygenases. <i>Catalysts</i> , 2019, 9, 1001.	3.5	9
45	Isolation and Culture of Mouse Hepatocytes: Gender-Specific Gene Expression Responses to Chemical Treatments. <i>Methods in Molecular Biology</i> , 2015, 1250, 3-12.	0.9	9
46	Deletion of genes from the mouse genome using Cre/loxP technology. <i>Methods in Molecular Biology</i> , 2006, 320, 307-19.	0.9	8
47	A novel mutation in the flavin-containing monooxygenase 3 gene ( <i>FMO3</i> ) of a Norwegian family causes trimethylaminuria. <i>Molecular Genetics and Metabolism</i> , 2009, 98, 198-202.	1.1	6
48	Pharmacogenetic testing in the UK clinical setting. <i>Lancet</i> , The, 2013, 381, 1903.	13.7	6
49	Microinjection of targeted embryonic stem cells and establishment of knockout mouse lines for <i>Fmo</i> genes. <i>Methods in Molecular Biology</i> , 2006, 320, 329-41.	0.9	6
50	Pyruvate-induced Long-term Maintenance of Glutathione S-Transferase in Rat Hepatocyte Cultures. <i>ATLA Alternatives To Laboratory Animals</i> , 2001, 29, 335-346.	1.0	4
51	Transfection of Primary Cultures of Rat Hepatocytes. , 2006, 320, 273-282.		3
52	Regulation of cytochrome P4502B2 gene expression. <i>Biochemical Society Transactions</i> , 1994, 22, 125S-125S.	3.4	2
53	Microinjection of Targeted Embryonic Stem Cells and Establishment of Knockout Mouse Lines for <i>Fmo</i> Genes. , 2006, 320, 329-342.		2
54	Flavin-containing monooxygenases: new structures from old proteins. <i>Nature Structural and Molecular Biology</i> , 2020, 27, 3-4.	8.2	2

#	ARTICLE	IF	CITATIONS
55	Expression in a baculovirus system of a cDNA encoding human CYP2A6. <i>Biochemical Society Transactions</i> , 1994, 22, 122S-122S.	3.4	1
56	Expression of Recombinant Flavin-Containing Monooxygenases in a Baculovirus/Insect Cell System. , 2006, 320, 39-60.		1
57	The integration and interpretation of pharmacogenomics â€” a comparative study between the United States of America and Europe: towards better health care. <i>Drug Metabolism and Personalized Therapy</i> , 2016, 31, 91-96.	0.6	1
58	Cell systems capable of sustaining phenobarbital induction of CYP2B genes. <i>Biochemical Society Transactions</i> , 1994, 22, 120S-120S.	3.4	0
59	IMMORTALIZED HEPATOCYTES FROM TRANSGENIC MICE. <i>Biochemical Society Transactions</i> , 1997, 25, 42S-42S.	3.4	0
60	Determination of Cellular Localization of Expression of Flavin-Containing Monooxygenase Genes in Mouse Tissues by <i>In Situ</i> Hybridization. , 2006, 320, 295-306.		0
61	Deletion of Genes From the Mouse Genome Using <i>Cre/ loxP</i> Technology. , 2006, 320, 307-320.		0